The Board of Shanghai Haohai Biological Technology Co., Ltd. announced that Mr. Gan Renbao did not offer himself for re-election due to age considerations and Mr. Li Yuanxu did not offer himself for re-election upon considering his tenure as an independent non-executive Director for almost nine years. Due to the election of the new session of the Board, the tenures of Mr. Gan Renbao and Mr. Li Yuanxu, Directors of the Third Session of the Board have expired and they will no longer serve as Directors or hold any positions in the Board committees in the Company from the date of approval of election of the Fourth Session of the Board at the AGM. The Board announced that immediately following the AGM, Dr. Hou Yongtai was unanimously elected by the Board as the Chairman of the Fourth Session of the Board. His term of office would be consistent with the term of office of his directorship. Also, immediately following the AGM, Mr. Liu Yuanzhong was unanimously elected by the Supervisory Committee as the Chairman of the Fourth Session of the Supervisory Committee of the Company. His term of office would be consistent his term of office as a Supervisor. The Board announced that, with effect from June 27, 2019, Mr. Zhu Qin, an independent non-executive Director of the Company, has been appointed as the chairman of the nomination committee of the Board; Mr. Wong Kwan Kit, an independent non-executive Director of the Company, has been appointed as a member of the nomination committee of the Board and of the audit committee of the Board; and Mr. Chen Huabin, an independent non-executive Director of the Company, has been appointed as a member of the remuneration committee of the Board and of the strategy committee of the Board.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.